Skip to main content


Figure 4 | Journal of Translational Medicine

Figure 4

From: Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

Figure 4

Unsupervised hierarchical clustering of clinical parameters and tetramer, ELISPOT, HLA-DR, CD45RO, and FoxP3 QPCR for all patients and available time points. Each column represents results for 1 patient. The first 5 rows describe clinical features of patients, including response to therapy (0 = No response; 1 = Response), site (U = University of California, Los Angeles; M = MD Anderson), sex (M = Male; F = Female), stage (3 = IIIc; 4 = IV), age, and metastasis (0 = Lung; 1 = Nodes; 2 = Liver; 3 = Subcutaneous; 4 = Skin; 5 = Stomach; 6 = Adrenal; 7 = Kidney). The rest of the rows represent test results at different time points after dosing. White represents no change (0 value) or absence of data (which is not included in the clustering algorithm). Red and shades of red represent positive changes on a scale of 1 to 4. Blue and shades of blue represent negative changes on a scale of 1 to 4. Data are normalized to a -4 to +4 scale as described in Table 2. ELISPOT = Enzyme-linked immunospot; HLA = Human leukocyte antigen; QPCR = Quantitative polymerase chain reaction; EBV = Epstein-Barr virus; MART1 = Melanoma-associated antigen recognized by T cells; EOS = End of study.

Back to article page